AOA Dx

Ovarian cancer patients deserve more timely and effective care. Rachel was placed on a 9-month waiting list for the removal of what was initially believed to be a benign cyst. Tragically, it turned out to be ovarian cancer. "Her first symptom was extreme fatigue." "I felt like I was 70 years old. I had to sleep as soon as I got home from work just to make it through the evening." When bloating followed, Rachel sought medical attention. An ultrasound revealed a mass on her ovary. Despite this, she was reassured that it was likely benign. Early detection is crucial to identify and address any suspicious masses. At AOA Dx, we work every day to make this a reality.

AOA Dx is excited to announce that this weekend at the Society of Gynecologic Oncology Annual Conference in Seattle, our co-founder Anna Milik Jeter and Chief Scientific Officer Abigail McElhinny presented our latest data! The data demonstrate how AOA's innovative multi-omic assay, leveraging novel lipids, effectively differentiates ovarian cancer (across all stages) from non-cancers in a complex symptomatic population. This advancement truly has the potential to transform early detection of ovarian cancer and we can't wait to share more with you soon. Stay tuned!

This week, our CEO + Co-Founder Oriana Papin-Zoghbi spoke on the panel "All-In: Global & Homegrown Companies Colorado Proud" at the 2025 Life Sciences Conference & Expo alongside: Michael Tranmer?- Senior Vice President and General Manager, Boulder Facility, AGC Biologics, Sally Dyer?- SVP, General Manager, Colorado Operations, Umoja Biopharma Derek Kronberg, BCT?- VP Global Process Engineering, Terumo Blood and Cell Technologies Joel Basken, PhD?- Director of Operations, Enveda Biosciences Sid Dixon?- Senior Director, Tenant Advisory Group, Cushman & Wakefield The panel centered around homegrown Colorado companies and companies relocating to Colorado from the coasts are investing in new labs and manufacturing facilities, drawing on the states’ scientific community, and building the next generation of the industry’s workforce. ??

At AOA Dx, we echo the World Economic Forum's recent call for increased investments in women's health diagnostics to drive health equity. 30 years after the 1995 Beijing Declaration, significant barriers remain, including access to accurate diagnostics. Despite diagnostics influencing 70% of clinical decisions, less than 5% of healthcare spending is allocated to it. As we develop our early detection test for ovarian cancer, we aim to reduce disparities and improve outcomes for all women. We must prioritize investment in women's health diagnostics to ensure timely, equitable care for all!

This weekend our CSO Abigail McElhinny and CRO Anna Milik Jeter will be at the Society of Gynecologic Oncology Annual meeting! Don't miss our poster presentation on March 16th. Details below ??

Happy International Women's Day! Today serves as a powerful reminder that women’s health conditions are too often overlooked, misdiagnosed, or misunderstood. There's still much work to be done to ensure women receive the care and attention they deserve to improve their health. This requires increased investment, better resources, more dedicated research, and beyond. We are proud of our entire team at AOA Dx for being part of this change!?? ??

The American Cancer Society's 2025 Cancer Facts & Figures report sheds light on the significant progress we've made in the fight against cancer, from advances in early detection to improved five-year survival rates. However, it also reveals ongoing disparities, particularly among women and minority groups. Cancer incidence among women continues to rise, and Native American and Black Americans are twice as likely to die from cancer compared to their White counterparts. The report also shines a light on the the critical need for early detection of ovarian cancer, highlighting that many women experience symptoms months before diagnosis. Early triage of symptomatic women is essential to improving outcomes, and it's a mission that AOA is dedicated to addressing. Check out the full report here:

Throwback Thursday! Our Chief Scientific Officer, Abigail McElhinny presented our latest data readout at PMWC - Precision Medicine World Conference! The results demonstrate strong performance?in detection of ovarian cancer?in the intended use population: women with nonspecific abdominal symptoms. Generated through a multi-omic approach to early cancer detection,?these?data?highlight?AOA’s potential to drive innovation in diagnostic tools for women’s health. ?? Ft: Anna Milik Jeter

Today, we want to spotlight the groundbreaking work of Dr. Barbara Goff and colleagues from the University of Washington. Dr. Goff highlighted the symptomatic nature of ovarian cancer, even in its earliest stages. Her research led to the creation of the Ovarian Cancer Symptom Index, which links six persistent symptoms to a higher likelihood of the disease. This index now serves as the foundation of key clinical guidelines, enabling physicians to better identify women at risk. Dr. Goff’s work is central to our research mission, particularly our goal of developing a simple blood test to triage women with ovarian cancer symptoms. As we approach this milestone, we aim to revolutionize early detection and improve outcomes for women diagnosed with ovarian cancer. https://lnkd.in/dCHWWDd4

The World Ovarian Cancer Coalition has just released the Socioeconomic Burden of Ovarian Cancer in 11 Countries Study, now published in JCO Global Oncology. Co-authored with RTI International and with input from the World Health Organization, the study is the first to assess the health, economic, and social burden of ovarian cancer across 11 countries. It builds on the Every Woman Study? series, which documented the experiences of nearly 4,000 women. The study reveals a staggering $70B cost of ovarian cancer, with 90% attributed to lost lives. Despite advances, survival rates remain slow to improve compared to breast cancer. By 2050, over half a million women will be diagnosed annually, and nearly 350,000 will die from the disease each year. Without action, almost 8 million women could die by 2050, with the greatest impact on low- and middle-income countries. It’s crucial for improving outcomes, and at AOA Dx, we are committed to making this a reality for patients. Our mission is to transform the future for women facing ovarian cancer by bringing early detection to the forefront. Check out the full study here: https://lnkd.in/eEYBhR5N